Randomised controlled trial targeting habit formation to improve medication adherence to daily oral medications in patients with gout

Constance P Fontanet,1,2 Niteesh K Choudhry,1,2 Wendy Wood,3 Ted Robertson,4 Nancy Haff,1,2 Rebecca Oran,1 Ellen S Sears,1,2 Erin Kim,1,2 Kaitlin Hanken,1,2 Renee A Barlev,1,2 Julie C Lauffenburger,1 Candace H Feldman2,5

ABSTRACT

Introduction Medication adherence for patients with chronic conditions such as gout, a debilitating form of arthritis that requires daily medication to prevent flares, is a costly problem. Existing interventions to improve medication adherence have only been moderately effective. Habit formation theory is a promising strategy to improve adherence. The cue-reward-repetition principle posits that habits are formed by repeatedly completing an activity after the same cue and having the action rewarded every time. Over time, cues become increasingly important whereas rewards become less salient because the action becomes automatic. Leveraging the cue-reward-repetition principle could improve adherence to daily gout medications.

Methods and analysis This three-arm parallel randomised controlled trial tests an adaptive intervention that leverages the repetition cue-reward principle. The trial will be conducted in August 2021 in Boston, Massachusetts, USA. Eligible patients are adults with gout who have been prescribed a daily oral medication for gout and whose most recent uric acid is above 6 mg/dL. Participants will be randomised to one of three arms and given pill bottles. In the intervention arms, participants will select a daily activity to link to their medication-taking (cue) and a charity to which money will be donated every time they take their medication (reward). Participants in Arm 1 will receive reminder texts about their cue and their charity reward amount will be US$0.50 per day of medication taken. Arm 2 will be adaptive; participants will receive a US$0.25 per adherent-day and no reminder texts. If their adherence is <75% 6 weeks post-randomisation, their reward will increase to US$0.50 per adherent-day and they will receive reminder texts. The primary outcome is adherence to gout medications over 18 weeks.

Ethics and dissemination This trial has ethical approval in the USA. Results will be published in a publicly accessible peer-reviewed journal.

Trial registration number NCT04776161

INTRODUCTION

Non-adherence to evidence-based prescription medications results in preventable morbidity and mortality for middle-aged and older adults.1–4 Studies have consistently shown that among patients with chronic illnesses, 50% of medications are not taken as prescribed.1 5 For patients who have gout, the most common chronic inflammatory arthritis in the USA,6 poor adherence to urate-lowering therapy (ULT) is a key reason why patients fail to reach treatment goals and have debilitating arthritis flares.7

Barriers to adherence are numerous, and include cost, unwanted side effects, and forgetfulness among many others.8 9 Interventions to improve adherence have focused on increasing knowledge about the importance of medications8 9 or motivation to take medications.4 Unfortunately, even the most successful of these approaches have been only modestly effective and positive results are generally only seen over the short term.1 12

One promising strategy to increase medication adherence in significant and sustainable ways is approaching medication-taking as a
daily habit. Taking a medication every day is similar to other repetitive behaviours that must be performed consistently, such as brushing one’s teeth every morning or washing one’s hands after using the bathroom. In these cases, people who consistently act in healthy ways do so out of habit. The repetition-cue-reward model proposes that habit formation has three central components: behavioural repetition, associated context cues, and rewards. Under this model, habits are formed by completing an activity in contiguity with a particular cue, and having the action rewarded. When this sequence is repeated, cues become increasingly important, whereas rewards become increasingly less salient because a level of automaticity has been reached. Once habits are formed, they guide actual behaviour rather than intention. For example, eating habits are stronger determinants of food choices than eating intentions or susceptibility to eating temptations.

Accordingly, principles of habit formation have the potential to improve medication adherence by transforming the act of medication-taking into an automatic action. Therefore, we propose a randomised controlled trial that aims to identify whether an intervention targeting habit formation using the cue-reward repetition model has the potential to improve adherence to chronic, daily ULT in patients with gout.

**METHODS**

**Study design**

This study is a pragmatic, prospective, three-arm parallel randomised controlled trial designed to evaluate a habit formation intervention for improving adherence to daily ULT among individuals with gout (see figure 1). Enrolment began in August 2021 and we plan to complete follow-up by April 2022.

**Study setting and participants**

We will enrol patients who are currently receiving gout care at a rheumatology or primary care practice affiliated with Brigham and Women’s Hospital, a large academic medical centre in Boston, Massachusetts, USA caring for over 4000 patients with gout every year. Potentially eligible participants are individuals who are at least 18 years old with gout, who receive a stable dose of oral ULT, and whose most recent uric acid level within the last 6 months is >6 mg/dL (target therapeutic level while on ULT is <6). Eligible patients must also have a smartphone with a data plan or WiFi at home and be willing to use electronic pill bottles for their gout medications for the duration of the study. These criteria were chosen because the use of electronic pill bottles requires smartphone connectivity to record adherence. Finally, because the intervention is currently only available in the English language, participants will be required to have a basic working knowledge of English. Patients will be excluded if they are currently pregnant.

![Figure 1: Trial design.](image-url)
Recruitment and screening
Due to social distancing restrictions put in place because of the COVID-19 pandemic, we will screen and recruit participants remotely (see figure 2). We will identify eligible participants using electronic health record (EHR) data. For patients identified through the EHR, we will first contact the patients’ rheumatologist or primary care physician for their approval to approach the patient. If the provider does not opt out an identified patient, the patient will be sent a letter with information about the study inviting them to participate. One week later, patients will be contacted by phone to ask about their interest in the study and to confirm eligibility. If patients agree to participate, they will provide electronic written informed consent for all study procedures, including the use of text messages, and complete baseline questionnaires using REDCap (Research Electronic Data Capture),15 a secure web-based data collection tool.16 17 This paperless consent process was approved by our Institutional Review Board. At the end of the enrolment visit, they will be randomised to one of three arms. All participants will then be mailed up to two electronic pill bottles manufactured by Pillsy along with written instructions for setup. Participants in the intervention arm will also be given a guide to assist them in selecting a cue (see online supplemental file 1).

Before beginning follow-up, subjects in all arms will be contacted to review procedures, confirm the functionality of their bottles, and verify cellphone numbers for delivery of the intervention.

Randomisation
Study enrolment began in August 2021 and is anticipated to be completed by January 2022. In order to improve balance between the three arms, we will use block randomisation stratified by (1) recruitment method, specifically through rheumatology or primary care practices and (2) baseline uric acid >6.0–8.0 mg/dL or >8.0 mg/dL. Participants will be randomised by research assistants in a 1:1:1 ratio within blocks of three participants to one of three treatment arms using the randomisation module integrated in REDCap.16 17

Interventions
This trial will have two intervention arms and one control arm. Both intervention arms will include a cue-reward ‘couplet’, but the intensity of the couplet will depend on arm assignment. The study design and intervention components are described further in figure 1.

Arm 1: non-adaptive intervention
Participants in the first intervention arm will choose a lifestyle ‘cue’ and receive a reward over a 12-week period. The cue will be selected by each participant through a goal-setting exercise during which they will identify the activity they want to link to their medication-taking (see online supplemental file 1). For example, a participant who takes their medication in the morning may elect to link tooth brushing with medication-taking. Participants will select their cue assisted by study staff during the device setup call. If adherence falls below 75%, for the prior 4 days, participants will receive a text message reminding them of the cue they decided to link to their medication-taking (see figure 3 and online supplemental file 2). The ‘reward’ will consist of a charitable donation every time the participant takes their medication. Participants will choose a charity during the enrolment visit, in specific a local animal shelter, a local food bank, or UNICEF. To clearly link the reward to the act of medication-taking, a sticker with the charity logo will be placed under the patient’s pill bottle cap prior to mailing it to the participant so that they are reminded of the donation every time they take their medication (see online supplemental file 2).
file 3). Every day that the participant takes their medication as prescribed, US$0.50 will be donated to their charity of choice. Participants will receive texts every 4 days summarising how much money was donated on their behalf and the potential impact of their donation (see online supplemental file 4). For example, participants who chose the local food bank as their charity could receive a text message that states ‘By taking your medication, you helped people struggling with hunger. Thanks to you, the Greater Boston Area Food Bank has been able to prepare eight free meals.’

After the 12-week study period, participants will then be observed for 6 weeks without any intervention.

To determine the amount of the reward and whether a text reminder about the cue needs to be sent, adherence from the prior 4 days will be calculated by dividing the number of times a patient opened the pill bottle by the number of doses expected to be taken over 4 days. For patients on more than one medication, the values for each medication are averaged. Adherence values will range from 0% to 100%. To avoid erroneously classifying repeated bottle openings over a short period of time as multiple unique medication-taking events, we only count a maximum of 1 opening event per 3-hour period; opening events more than 3 hours apart are classified as separate doses.

Arm 2: adaptive intervention
Participants in the second intervention arm will receive cues and rewards as with Arm 1 for the first 6 weeks of the study period, although the amount of the reward will be US$0.25 per day. At the 6-week point, participants who remain non-adherent will be intensified and begin receiving text messages as in Arm 1 reminding them of the activity they decided to link to their medication-taking at the start of the intervention (see figure 3 and online supplemental file 4). They will receive these text messages over the following 6 weeks. Additionally, non-adherent participants will also see their charity reward increased to US$0.50 per day to match the non-adaptive intervention arm. Participants will then be observed for 6 weeks without any intervention.

Arm 3: control
Participants in the control arm will not receive any intervention but will receive electronic pill bottles to monitor their adherence over 18 weeks.

Data collection and management
Participants will be asked to complete surveys at baseline to capture demographic information, medical history, disease activity, and self-reported medication adherence (see online supplemental file 5). Additionally they will complete the Self-Report Behaviour Automaticity Index, which assesses whether participants complete a given activity (such as medication-taking) automatically, for example by asking if they start doing it before they realise they are doing it. We will also use the routine assessment questionnaire developed by Heintzelman and King, which provides a measure of how participants integrate a certain activity into their routine. Additionally, we will inquire about intentions and perceptions of medications using a modified version of the HIV Intention and Knowledge scale. Coexisting medical conditions and uric acid values will be extracted from the patient’s EHR. At the end of the study, participants will be asked to complete a follow-up questionnaire mirroring questions from the baseline questionnaire about medication-taking automaticity, integration of medication-taking into their routine, and intentions and perceptions regarding their medications. In addition, we will ask for feedback regarding the usefulness, acceptability, and feasibility of the intervention. These data will be electronically recorded in a REDCap database. Once recorded, data will be locked to prevent changes. After the end of follow-up, participants

---

Figure 3  Daily procedures. REDCap; Research Electronic Data Capture.
will use the uric acid level value available in the EHR and will include change in uric acid level from baseline. We explore the feasibility and acceptability of the intervention on adherence and over the follow-up period through change in automaticity and sense of routine that these devices offer (e.g., alerts when doses are due) will be disabled. Additionally, bias would be non-differential and the observer effects of the devices will decrease over time, as has been observed in other medication adherence studies. The use of pill caps will allow us to evaluate objective medication-taking (both to classify patterns and evaluate trial outcomes) over a short period of time.

Outcomes

The trial’s primary outcome is adherence to gout medications over the 18-week follow-up period after randomisation. We will use an average of averages approach, where medication adherence will be measured as the proportion of times a participant opened the electronic pill bottle out of the number of doses prescribed for each bottle in each day, averaged across the study medications and over the follow-up period.

Secondary outcomes will include habit formation through change in automaticity and sense of routine from baseline, as well as possible changes in intention or perceptions of gout medications. Additionally, we will explore the feasibility and acceptability of the intervention within the intervention arms. Exploratory outcomes will include change in uric acid level from baseline. We will use the uric acid level value available in the EHR closest to each participant’s end of follow-up date to calculate change in uric acid level. Since uric acid levels may not be collected on a regular basis and may be collected differentially for adherent patients, we expect 15%–20% missing data and will consider the results of this analysis exploratory.

The outcomes will be evaluated using intention-to-treat principles among all randomised participants. Change in mean adherence and mean uric acid level will be analysed using generalised estimating equations with a link function and normally distributed errors. If there are differences in baseline characteristics between study groups, we will repeat our analyses after adjusting for these covariates. If a substantial amount of subjects have missing outcome data, we will repeat our analyses using the latest postrandomisation lab values available and using multiple imputation.

We powered the study to detect a clinically meaningful 20% relative increase in adherence between each intervention arm and our control arm. We estimated that we would have 80% power at an alpha threshold of 0.05 to detect this effect by randomising 20 participants to each arm, assuming that the baseline rate of adherence to urate-lowering therapy in our patient population is 50%. Data will then be analysed with SAS V.9.4. Access to the deidentified data sets will be limited to the study authors.

Patient and public involvement

We used electronic pill bottles to monitor medication use in a previous qualitative study among patients with gout to learn more about their experiences with taking daily oral medications. These interviews helped inform the design of our intervention.

DISCUSSION

A habit is an action that is triggered automatically in response to a contextual cue. For example, getting into a car can be the contextual cue for the action of putting on a seatbelt. Once habits are formed, conscious attention to the action diminishes as automaticity takes over. Habit formation theory has already had practical implications for health promotion. For example, a randomised controlled trial of a low-intensity habit formation intervention for weight control led to increased weight loss maintained over time. We hypothesise that creating a system of cues and rewards for patients can increase automaticity of medication-taking and improve adherence to oral medications intended for daily use. We anticipate that this study will also help reduce gout flares.

There are a few limitations to this study. First, we will enrol patients who have access to a cell phone. While cell phone usage is almost ubiquitous in the USA, there

Statistical analysis, sample size and power estimates

We will include all patients randomised in the study in these analyses. We will report the means and frequencies of baseline variables, including demographics, baseline medication use and self-reported adherence, coexisting illnesses and self-reported automaticity separately for the three intervention arms. Comparisons of these values for the two intervention arms to the usual care arm will be performed using t-tests and \( \chi^2 \) tests and their non-parametric analogues, as appropriate.


BMJ Open: first published as 10.1136/bmjopen-2021-055930 on 24 November 2021. Downloaded from http://bmjopen.bmj.com/ on December 7, 2021 by Partners HealthCare System. Protected by copyright.
are still individuals without one who would not be able to participate, which may limit the generalisability of the study. Second, while we will measure adherence outcomes after the intervention has been removed for 6 weeks, we will be measuring short-term outcomes and are therefore unable to understand the long-term effects of our intervention. Finally, the use of electronic pill bottles and frequent text messages may result in a Hawthorne effect, although we expect the effect to decrease over time and be non-differential across groups. Similarly, while patients in the control group may already have a cue in place that triggers medication-taking, we expect that most patients enrolled will be non-adherent as we are requiring an elevated uric acid, which may suggest suboptimal ULT use. Randomisation will also limit any bias.

In conclusion, this trial will evaluate the impact of an individually-tailored habit formation intervention to improve adherence to daily medications for patients who suffer from gout. If the intervention is effective, this strategy could be tested in and scaled to other diseases, clinical environments, and health behaviours.

ETHICS AND DISSEMINATION

This protocol has been approved by the Institutional Review Board at Brigham and Women’s Hospital. No data monitoring committee was deemed necessary by the human subjects’ oversight boards. Written informed consent will be obtained from all participants. Data analysts at the end of the study will be blinded to arm assignment; however, patients are not blinded due to the nature of the interventions. The findings from this work will be published in a peer-reviewed journal and publicly accessible.

Author affiliations
1 Center for Healthcare Delivery Sciences (C4HDS), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
3 Department of Psychology, University of Southern California, Los Angeles, California, USA
4 Ideas42, New York, New York, USA
5 Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Twitter Julie C Lauffenburger @jlauffen

Acknowledgements The authors wish to thank the Digital Care Transformation team at BWH, which responsible for managing Microsoft Dynamics 365 SMS texting platform.

Contributors All authors meet International Committee of Medical Journal Editors (ICMJE) criteria. CPF contributed meaningfully to trial or intervention design and implementation and drafted the trial protocol and manuscript. CHF had overall responsibility for the trial design and trial protocol, and helped draft the trial protocol and manuscript. NKC is the coprincipal investigator, had overall responsibility for the trial design and trial protocol, and helped draft the trial protocol and manuscript. WW, TR, NH, RO, ESS, EK, KH, RAB and JCL contributed meaningfully to trial or intervention design and implementation as well as the manuscript. All authors contributed to the refinement of the study protocol and approved the final manuscript.

Funding Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG064199 to BWH (Choudhry PI). CHF is supported by NIH NIAMS K23 AR071500.

Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests CHF serves in unpaid positions on the Board of Directors of the American College of Rheumatology and on the Medical-Scientific Advisory Council of the Lupus Foundation of America. She receives research support from Pfizer Pharmaceuticals unrelated to this work. NKC is a consultant to and holds equity in RxAnthe, unrelated to this work. He receives grant funding, payable to his institution, from Boehringer Ingelheim and Humana, also unrelated to the current work. RAB is funded by an unrestricted educational grant from Boehringer Ingelheim to the Brigham and Women’s Hospital, unrelated to the current work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Constance P Fontanet http://orcid.org/0000-0002-8253-1598
Julie C Lauffenburger http://orcid.org/0000-0002-4940-4140

REFERENCES


